UNSPSC 51371509: Tilidine hydrochloride

This classification denotes an opioid analgesic C17H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4YI72J28N9, chemically known as 3-cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride (trans)-(+/-)-, but more generally known as tilidine hydrochloride, which bears US NIH Compound Identifier 32328. European Medicines Agency schedules Tilidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15573MIG.

Most nations, for tariff and trade purposes, schedule tilidine hydrochloride under HS 29224400 and SITC 51465. As of Q4 2014, TILIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2CCCCC2.CL.

UNSPSC 51371509 Tilidine hydrochloride is a Commodity code that nominally identifies a specific opioid pharmaceutical product, but the recent state and local opportunities tagged under this code diverge sharply from the narrow product scope. State and local governments are actually procuring pharmaceutical supply arrangements through this code covering naloxone, generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing vehicles and direct-to-manufacturer models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances administering agreements on behalf of multiple state and local governments (MMCAP, administered by the Minnesota Department of Administration). The procurement activity reflects a shift toward broader pharmaceutical sourcing, generic drug programs, and opioid-response products rather than single-entity drug procurement. Recent opportunities show state and local governments seeking to establish supplier networks that can provide volume pricing, direct manufacturer relationships, and supply chain flexibility to support public health initiatives and employee health plans across multiple jurisdictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract award to become effective July 1, 2026; the MMCAP contract requires vendors to work through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and demands compliance with cGMP, the Drug Supply Chain Security Act, and a 3 percent administrative fee structure. The mismatch between the code's nominal scope (tilidine hydrochloride, a specific opioid) and actual procurement activity (broad pharmaceutical supply platforms) suggests this code may be applied inconsistently or as a catch-all for pharmaceutical purchasing in some state and local jurisdictions.